The Prognostic Value of De Ritis (AST/ALT) Ratio in Patients After Surgery for Urothelial Carcinoma: a Systematic Review and Meta-analysis

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2020 Feb 12

PMID 32042266

Citations 10

Authors

Xu Hu

Wei-Xiao Yang

Yan Wang

Yan-Xiang Shao

San-Chao Xiong

Xiang Li

Affiliations

Soon will be listed here.

Abstract

Background: Recently, the De Ritis (AST/ALT) ratio has been considered as a prognostic biomarker for various malignancies. We conducted this systematic review and meta-analysis to explore the prognostic value of preoperative De Ritis ratio in patients after surgery for urothelial carcinoma.

Methods: We searched the online database Embase, PubMed and Cochrane Library up to October 2019. The hazard ratio (HR) and 95% confidence interval (CI) were extracted from the studies.

Results: A total of 8 studies incorporating 3949 patients were included in the quantitative synthesis. We observed that elevated preoperative De Ritis ratio is associated with inferior OS (HR = 1.97; 95% CI 1.70-2.28; P < 0.001), CSS (HR = 2.40; 95% CI 2.02-2.86; P < 0.001), RFS (HR = 1.31; 95% CI 1.11-1.54; P = 0.001), PFS (HR = 2.07; 95% CI 1.68-2.56; P < 0.001) and MFS (HR = 2.39; 95% CI 1.16-4.91; P = 0.018). Stratified by diseases, the elevated De Ritis ratio also served as an unfavorable factor.

Conclusion: The elevated preoperative De Ritis ratio is an unfavorable factor for patients with urothelial carcinoma. In patients with BC and UTUC, the elevated preoperative De Ritis ratio is also associated with poor prognosis. But De Ritis ratio must be validated in large, independent cohorts before it can be applied widely.

Citing Articles

Analysis of Calculated Liver Scores for Long-Term Outcome in 423 Cutaneous Melanoma Patients.

Abu Rached N, Reis M, Stockfleth E, Kapynen R, Gambichler T Cancers (Basel). 2024; 16(18).

PMID: 39335187 PMC: 11429836. DOI: 10.3390/cancers16183217.

Blood-, Tissue- and Urine-Based Prognostic Biomarkers of Upper Tract Urothelial Carcinoma.

Laszkiewicz J, Krajewski W, Sojka A, Nowak L, Chorbinska J, Subiela J Diagnostics (Basel). 2024; 14(17).

PMID: 39272712 PMC: 11393937. DOI: 10.3390/diagnostics14171927.

Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

Wetz C, Ruhwedel T, Schatka I, Grabowski J, Jann H, Metzger G Cancers (Basel). 2023; 15(24).

PMID: 38136263 PMC: 10741556. DOI: 10.3390/cancers15245717.

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [Lu]Lu-PSMA-617 Radioligand Therapy.

Gaal S, Huang K, Rogasch J, Jochens H, De Santis M, Erber B Cancers (Basel). 2023; 15(20).

PMID: 37894274 PMC: 10605155. DOI: 10.3390/cancers15204907.

Association of AST/ALT (De Ritis) ratio with sarcopenia in a Chinese population of community-dwelling elderly.

Wu C, Wang Q, Zhou C, Sun H, Lin Y, Jiao X Heliyon. 2023; 9(10):e20427.

PMID: 37822616 PMC: 10562753. DOI: 10.1016/j.heliyon.2023.e20427.

References

Margulis V, Shariat S, Matin S, Kamat A, Zigeuner R, Kikuchi E . Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115(6):1224-33. DOI: 10.1002/cncr.24135. View

Yuk H, Jeong C, Kwak C, Kim H, Ku J . De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study. Dis Markers. 2019; 2019:6702964. PMC: 6732616. DOI: 10.1155/2019/6702964. View

Takenaka Y, Takemoto N, Yasui T, Yamamoto Y, Uno A, Miyabe H . Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer. PLoS One. 2016; 11(10):e0164057. PMC: 5061313. DOI: 10.1371/journal.pone.0164057. View

Ha Y, Kim S, Chun S, Chung J, Choi S, Lee J . Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy. BMC Urol. 2019; 19(1):10. PMC: 6345026. DOI: 10.1186/s12894-019-0439-7. View

Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S . The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008; 245(3):194-205. DOI: 10.1016/j.tox.2007.11.021. View

Cho Y, Hwang J, Chung H, Kim M, Hwang E, Jung S . The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma. Int Urol Nephrol. 2017; 49(8):1383-1390. DOI: 10.1007/s11255-017-1613-z. View

Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R . The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma. J Urol. 2015; 194(1):30-5. DOI: 10.1016/j.juro.2015.01.083. View

DE RITIS F, Coltorti M, Giusti G . An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957; 2(1):70-4. DOI: 10.1016/0009-8981(57)90027-x. View

10.

Lee H, Choi Y, Sung H, Han D, Jeon H, Jeong B . De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery. Clin Genitourin Cancer. 2016; 15(3):e379-e385. DOI: 10.1016/j.clgc.2016.08.023. View

11.

Witjes J, Lebret T, Comperat E, Cowan N, De Santis M, Bruins H . Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2016; 71(3):462-475. DOI: 10.1016/j.eururo.2016.06.020. View

12.

Nishikawa M, Miyake H, Kurahashi T, Fujisawa M . Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy. Int J Clin Oncol. 2017; 23(1):151-157. DOI: 10.1007/s10147-017-1184-0. View

13.

Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H . Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2014; 60(128):1892-5. View

14.

Li Y, Fang D, Bao Z, He A, Guan B, He S . High aspartate transaminase/alanine transaminase ratio predicts poor prognosis in patients with localized upper tract urothelial cancer: a propensity score-matched study in a large Chinese center. Onco Targets Ther. 2019; 12:2635-2648. PMC: 6489587. DOI: 10.2147/OTT.S193771. View

15.

Dorward A, Sweet S, Moorehead R, Singh G . Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. J Bioenerg Biomembr. 1997; 29(4):385-92. DOI: 10.1023/a:1022454932269. View

16.

Conde V, Oliveira P, Nunes A, Rocha C, Ramalhosa E, Pereira J . The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Exp Cell Res. 2015; 335(1):91-8. DOI: 10.1016/j.yexcr.2015.04.007. View

17.

Greenhouse W, Lehninger A . Occurrence of the malate-aspartate shuttle in various tumor types. Cancer Res. 1976; 36(4):1392-6. View

18.

Gorgel S, Kose O, Koc E, Ates E, Akin Y, Yilmaz Y . The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy. Int Urol Nephrol. 2017; 49(9):1577-1583. DOI: 10.1007/s11255-017-1648-1. View

19.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

20.

Lughezzani G, Burger M, Margulis V, Matin S, Novara G, Roupret M . Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012; 62(1):100-14. DOI: 10.1016/j.eururo.2012.02.030. View